Drugs / SBT777101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06361836 | Oct 2024 → Nov 2026 expected | hidradenitis suppurativa | Sonoma Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06201416 | Mar 2024 → Nov 2026 expected | rheumatoid arthritis | Sonoma Biotherapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-14 | Sonoma Biotherapeutics, Inc. | Results Sonoma Biotherapeutics Announces Upcoming Late-Breaking Oral and Poster Presentations at the 2025 American College of Rheumatology (ACR) Convergence sonomabio.com ↗
Late-breaking oral presentation of interim safety and efficacy data from the phase 1 study of SBT-77-7101, including a favorable early safety profile, with preliminary clinical and mechanistic evidence of therapeutic activity in refractory rheumatoid arthritis |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-14 | Sonoma Biotherapeutics, Inc. | Sonoma Biotherapeutics Announces Upcoming Late-Breaking Oral and Poster Presentations at the 2025 American College of Rheumatology (ACR) Convergence sonomabio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBT777101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06201416 ↗ |
| Modality | Cell therapy | “autologous (using the patient's own cells) Treg cell therapy” NCT06201416 ↗ |
| Route | Intravenous | “two intravenous infusions of SBT777101” NCT06201416 ↗ |